STOCK TITAN
  1. Home
  2. News
  3. CRBU

Caribou Biosciences Inc - CRBU STOCK NEWS

Welcome to our dedicated news page for Caribou Biosciences (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Caribou Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Caribou Biosciences's position in the market.

News
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) will present initial dose expansion data from the CB-010 ANTLER Phase 1 Trial in relapsed/refractory B-NHL at the 2024 ASCO Annual Meeting. The company also announced another abstract presentation for the CB-012 AMpLify trial. The abstracts will be available on May 23, 2024, with poster presentations on June 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
conferences clinical trial
-
News
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Rhea-AI Summary
Caribou Biosciences announces an oral presentation on in vivo Cas12a chRDNA genome editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The presentation will focus on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption, with details on the title, presenter, date, time, session, and abstract number. The abstract will be available on the ASGCT Annual Meeting website on April 22, 2024, and the presentation on Caribou's website on May 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
-
News
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
Rhea-AI Summary
Caribou Biosciences, Inc. (CRBU) receives FDA clearance for IND application of CB-010, a CAR-T cell therapy for lupus nephritis and extrarenal lupus. GALLOP Phase 1 trial to start by YE 2024. Positive initial safety and efficacy in ANTLER trial for B-NHL. CB-010's potential to revolutionize lupus treatment by targeting CD19-positive B cells. CB-010 aims for sustained drug-free remission through deep depletion of disease-causing B cells. Unique chRDNA technology for precise CAR insertion in T cell genome. GALLOP trial to include partial HLA matching for improved outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
clinical trial
News
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced financial results for 2023, highlighting key achievements such as initiating final IND/CTA enabling studies for PBGENE-HBV, completing licensing agreements with Imugene, TG Therapeutics, and Caribou Biosciences, and completing a $40 million public offering to extend cash runway. The company aims to submit IND and/or CTA for PBGENE-HBV in 2024 and PBGENE-PMM in 2025, advancing gene editing programs and differentiating ARCUS within the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
earnings
-
News
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Caribou Biosciences, Inc. (CRBU) reports significant progress in clinical trials, dosing the 30th patient in the CB-010 ANTLER Phase 1 trial and initiating the CB-012 AMpLify Phase 1 trial. The company has $372.4 million in cash and securities to fund operations until Q1 2026. Financially, Caribou saw an increase in licensing revenue but also higher R&D and G&A expenses, resulting in a net loss for Q4 2023 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.47%
Tags
earnings
-
News
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Caribou Biosciences, Inc. (CRBU) announced the presentation of preclinical data on CB-012, an anti-CLL-1 CAR-T cell therapy for r/r AML at AACR Annual Meeting 2024. The therapy shows specific cytotoxicity in AML xenograft models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences clinical trial
News
Caribou Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Caribou Biosciences, Inc. (CRBU) announces its participation in key investor conferences to discuss its CRISPR genome-editing technology. The company will be present at Citi's 2024 Virtual Oncology Leadership Summit, Leerink Global Biopharma Conference, Barclays Global Healthcare Conference, and H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. Webcasts will be accessible on Caribou's website for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
News
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
Rhea-AI Summary
Caribou Biosciences, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced the appointment of Tim Kelly as the chief technology officer. Caribou highlighted the successful execution across its allogeneic CAR-T cell therapy platform and provided an outlook on multiple clinical catalysts planned for 2024. The company reported significant clinical highlights and corporate accomplishments in 2023, along with the anticipated milestones for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) has received positive feedback from the FDA on its Phase 3 randomized controlled trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy for second-line relapsed or refractory large B cell lymphoma. The FDA has accepted Caribou's proposed comparator arm of immunochemotherapy followed by high dose chemotherapy and autologous stem cell transplantation. The ongoing ANTLER Phase 1 trial is progressing well, with plans to report initial dose expansion data and the recommended Phase 2 dose for CB-010 in Q2 2024. Caribou aims to initiate a Phase 3 pivotal trial by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
clinical trial
News
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
CRBU Caribou Biosciences, Inc. reports progress in ANTLER Phase 1 trial and plans to share FDA feedback by year-end 2023. $396.7 million in cash expected to fund operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
earnings
Stock CRBU logo
Caribou Biosciences Inc

Nasdaq:CRBU

CRBU Rankings

#3298 Ranked by Market Cap
#4963 Ranked by Stock Gains
N/A Ranked by Dividends

CRBU Stock Data

379.32M
68.48M
10.14%
80.55%
11.3%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Berkeley

About CRBU

caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever"​ and the new york times has noted that "the pace of new discoveries and applications is dizzying."​ caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub